A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Status:
Completed
Trial end date:
2020-04-20
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate
the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who
are treatment naïve or previously treated.
An independent central pathology review of tumour samples will be used to confirm the
diagnosis of PRCC of all patients enrolling. However, locally available pathology results
confirming PRCC will be allowed for timely study entry.